Trial intelligence / Profile preview

Selexipag add-on therapy in children with pulmonary arterial hypertension

CTR20202573Phase 3Active

Sponsor
Actelion Pharmaceuticals Ltd
Start
Jul 2021
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2021; status: active.

02

Drugs

selexipag
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on CTR20202573.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20202573.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call